NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs
暂无分享,去创建一个
[1] D. Arnold,et al. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies , 2016 .
[2] M. Battaglini,et al. Long-term assessment of no evidence of disease activity in relapsing-remitting MS , 2015, Neurology.
[3] D. Arnold,et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. , 2015, The New England journal of medicine.
[4] K. Schmierer,et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? , 2015, Multiple sclerosis and related disorders.
[5] H. Weiner,et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.
[6] M. Racke,et al. Is no evidence of disease activity a realistic goal for patients with multiple sclerosis? , 2015, JAMA neurology.
[7] D. Arnold,et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. , 2015, JAMA neurology.
[8] Daniel C. Lee,et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. , 2015, JAMA.
[9] J. Johansson,et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[10] Christian Confavreux,et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.
[11] Jeffrey A. Cohen,et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.
[12] H. Atkins,et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper , 2012, Multiple sclerosis.
[13] G. Mancardi,et al. Autologous haematopoietic stem-cell transplantation in multiple sclerosis , 2008, The Lancet Neurology.